# Tulane COBRE for Clinical and Translational Research in Cardiometabolic Diseases

> **NIH NIH P20** · TULANE UNIVERSITY OF LOUISIANA · 2024 · $2,279,688

## Abstract

PROJECT SUMMARY/ABSTRACT (Overall)
Cardiometabolic diseases are the leading cause of death in the US and have a disproportionate impact on the
residents of Louisiana. During COBRE Phase 1, we have established the Tulane University Translational
Science Institute (TUTSI), developed a critical mass of clinical and translational researchers, and increased
scientific productivity in cardiometabolic diseases at Tulane University. Seven of 12 COBRE Research Project
Leaders (RPLs) and Pilot Project Leaders (PPLs) have been funded for one or more peer-reviewed research
projects from NIH and NSF. COBRE investigators have published 310 peer-reviewed scientific articles (140
from RPLs and PPLs and 170 from other COBRE investigators and collaborators) supported by the COBRE
Phase 1 grant (GM109036). The overall objective of this COBRE Phase 2 application is to further
develop and strengthen the clinical and translational research infrastructure at Tulane University and
to continuously expand and support a critical mass of investigators with expertise in clinical and
translational research in cardiometabolic diseases. The specific aims of this COBRE Phase 2 application
are: 1) to enhance and sustain TUTSI, a university-wide thematic multidisciplinary Center for clinical and
translational research on cardiometabolic diseases that motivates and facilitates interdisciplinary collaboration
among basic, clinical, and population scientists; 2) to develop and nurture the next generation of investigators
in clinical and translational science focused on cardiometabolic diseases; 3) to achieve the aims of the
innovative Research Projects proposed by our four RPLs, including to elucidate metabolomic mechanisms of
apolipoprotein L1 risk alleles associated with kidney disease progression in Black patients, to identify
biomarkers of type 2 diabetes in adipose tissue-derived extracellular vesicles, to investigate the interrelations
among amylase gene copy number variants, carbohydrate intake, and incident hyperglycemia and type 2
diabetes, and to test the intake-response effect of potassium supplementation on blood pressure in a
randomized controlled trial; and 4) to establish and strengthen a Clinical Research and Community
Engagement Core, Bioinformatics and Biostatistics Core, and Molecular Detection and Diagnostics Core and
expand innovative technical and methodologic support to RPLs, PPLs, other COBRE investigators, and
collaborators at Tulane University. Our COBRE program is unique because it addresses a significant public
health problem in Louisiana and the nation and focuses on novel clinical and translational research. If funded,
this COBRE Phase 2 program will play a central role in expanding and strengthening clinical and translational
research infrastructure and in recruiting, nurturing, and advancing a cadre of well-trained interdisciplinary
investigators in cardiometabolic disease research. The COBRE investigators will generate and apply new
knowledge to patie...

## Key facts

- **NIH application ID:** 10927208
- **Project number:** 5P20GM109036-08
- **Recipient organization:** TULANE UNIVERSITY OF LOUISIANA
- **Principal Investigator:** Katherine Teresa Mills
- **Activity code:** P20 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $2,279,688
- **Award type:** 5
- **Project period:** 2016-03-10 → 2027-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10927208

## Citation

> US National Institutes of Health, RePORTER application 10927208, Tulane COBRE for Clinical and Translational Research in Cardiometabolic Diseases (5P20GM109036-08). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10927208. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*